Short Chain Fatty Acids Targeted Panel

Metabolon Target

Short Chain Fatty Acids Targeted Panel

R 9 Metabolites

R Absolute Quantitation

R Rigorous Quality Control

R End-to-end Service

About Short Chain Fatty Acids

Short chain fatty acids (SCFAs) are produced in the colon by the gut microbiota. They are the end products of anaerobic fermentation of dietary fibers and protein/peptides in the small intestine. Their formation is the result of a complex interaction between diet, gut microbiota, and host. SCFAs influence the physiology of the colon serving as energy sources for host cells and the intestinal microbiota as well as participating in different host-signaling mechanisms. Eating high-fiber foods increases the production of SFCAs. Increased SFCAs may help treat inflammatory bowel disease and may decrease the risk of colon cancer.

Metabolomics reveals biological insights otherwise unseen. For a successful metabolomics study, both small molecule discovery and the ability to dig deeper into specific biomarkers of interest are needed to uncover actionable insights that propel new therapeutic developments. A specific combination of liquid chromatography-mass spectrometry (LC-MS) technology and expertise is required to identify these biomarkers of interest and develop assays that are sensitive enough to explore them fully.

At Metabolon, we understand the crucial role SFCAs play in gastrointestinal disorders, and we’ve established best-in-class expertise. This panel focuses on specific SFCAs and their metabolic pathways and can be used to track biomarkers and enhance biological understanding across preclinical and clinical research.

Short Chain Fatty Acids Targeted Panel Details

Swipe left/right to view the full table.

LLOQa
Metabolite Plasma/Serumb Fecesb Feces in OMNImet™·GUT tubec (µg/g dry feces)
Acetic Acid (C2) 1000 ng/mL 50.0 µg/g 1000 µg/g
Propionic Acid (C3) 100 ng/mL 25.0 µg/g 50 µg/g
Butyric Acid (C4) 25.0 ng/mL 25.0 µg/g 60 µg/g
Isobutyric Acid (C4) 25.0 ng/mL 5.00 µg/g 6.0 µg/g
Valeric Acid (C5) 25.0 ng/mL 5.00 µg/g 6.0 µg/g
Isovaleric Acid (C5) 25.0 ng/mL 5.00 µg/g 6.0 µg/g
2-Methylbutyric Acid (C5) 25.0 ng/mL 5.00 ug/g 5.0 µg/g
Caproic Acid (C6) 50.0 ng/mL 1.00 µg/g 2.0 µg/g
Lactic Acid (upon request)d 6.0 µg/g
aLower Limit of Quantitation (LLOQ) varies for each sample type.

bAssays with this sample type are for non-GxP testing and are not for diagnostic use.

cGood Clinical Practice (GCP) Assays. Lower Limit of Quantitation (LLOQ) stated is based on normalization using an average dry weight of feces. The actual measurement of the assay is the concentration of analyte in the OMNImet™·GUT tube containing human feces. Analyte concentrations in the OMNImet™·GUT tubes will be normalized by measured dry weight of feces unless otherwise requested.

dAvailable in select sample types only.

Analysis Method and Instrumentation:
LC-MS/MS (Agilent 1290 UHPLC/Sciex QTrap 5500)

Sample Type and Required Amounts
Sample Type Sample Requirement
Feces (wet weight) 200 to 500 mg
Plasma/Serum 100 to 150 µL
Bacterial cultures 300 to 500 µL
Urine 300 to 500 µL
Saliva 150 to 250 µL
Tissue 50 to 100 mg
Feces in OMNImet™·GUT tube Approx. 500 mg in OMNImet™·GUT tube, filled according to manufacturer specifications
Others on request

Disclaimer: Non-GxP assays are for Research Use Only and are not to be used for diagnostic purposes.

Delivering Absolute Quantification for Research and Biomarker Analysis

Our readily available or custom developed quantitative assays help you achieve your research and biomarker validation objectives with precise and fully validated methods. Our targeted assays and panels cover >1,000 metabolites and lipids across a wide range of biochemical classes, metabolic pathways, and physiological processes, and they can be customized to best fit any application.

Short Chain Fatty Acids Targeted Panel Applications

Gut Health

Gut health is important for overall health. Alterations of the gut microflora can cause several types of gastrointestinal disorders (including irritable bowel syndrome and viral hepatitis. In addition, gut microflora has also been implicated to play a role in autoimmune disease, skin disorders, as well as in diabetes, and obesity. The unique ability for metabolomics to identify microbial metabolites and how they regulate pathways in the host makes the technology a valuable tool for understanding gastrointestinal and other metabolic disorders.
gut health
Neuroscience

Neuroscience

Metabolomics provides valuable insight into the realm of brain science. Through dynamic bidirectional communication along the “gut-brain axis,” gut microbes collaborate with their hosts to regulate the development and function of the nervous system. For instance, in epilepsy, it is well-established that a low-carbohydrate, high-fat ketogenic diet (KD) can help treat refractory epilepsy, which affects more than a third of epileptic patients who don’t respond to existing anticonvulsive drugs. What scientists haven’t understood until recently is how this kind of diet translates to brain activity. The answer for this aspect of epilepsy lies in the gut microbiome. There are many other neurological disorders like Alzheimer’s disease, ALS, Parkinson’s disease and more. While so much remains to be understood about brain science, we do know that metabolomics is uniquely poised to understand the brain because of the ability of metabolites, small molecules, to cross the blood-brain barrier providing unique insights.

COVID

Recognized for our cutting-edge approach to metabolomics, Metabolon has been a valued resource for COVID-19 researchers worldwide. Our actionable metabolomic insights have fueled pivotal and high-profile studies like the National Institute of Allergy and Infectious Diseases (NIAID) IMPACC study research to improve understanding of high-risk patients and the Institute for Systems Biology research to improve understanding of high-risk patients. These and other metabolomics projects with actionable insights at Metabolon are helping get closer to the phenotype and pressing forward on COVID-19 answers.

covid

Big Insights with Metabolon

Cited in over 3,000 publications, we help scientists and manufacturers gain greater insight into their studies through metabolomics. See how our approach can become a successful part of your workflow.

Contact Us

Talk with an expert

Request a quote for our services or more information on sample types and handling procedures, need a letter of support, or simply have questions about how metabolomics can advance your research.

Corporate Headquarters

617 Davis Drive, Suite 100
Morrisville, NC 27560

Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709

+1 (919) 572-1711

+1 (919) 572-1721

International Headquarters

Metabolon GmbH

Zeppelinstraße 3
85399 Hallbergmoos
Germany

+49 89 99017752